AUTL Autolus Therapeutics ADS

Autolus Therapeutics to Present at the Cowen 40th Annual Health Care Conference

Autolus Therapeutics to Present at the Cowen 40th Annual Health Care Conference

LONDON, Feb. 25, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that Dr. Christian Itin, chairman and chief executive officer, will present at the Cowen 40th Annual Health Care Conference in Boston on Wednesday, March 4, 2020 at 10.00 am ET. The company will also host one-on-one meetings with attendees.

A live audio webcast of the presentation will be available on the investor relations section of Autolus’ website at . An archived replay will be available on the company’s website for a period of 90 days after the conference.

About Autolus Therapeutics plc 

Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. For more information, go to: . 

Contact:

Lucinda Crabtree, PhD

Vice President, Investor Relations and Corporate Communications

+44 (0) 7587 372 619

 

Julia Wilson

+44 (0) 7818 430877

  

Susan A. Noonan

S.A. Noonan Communications



EN
25/02/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Autolus Therapeutics ADS

 PRESS RELEASE

Autolus Therapeutics Presents Updated Clinical Data from the CARLYSLE ...

Autolus Therapeutics Presents Updated Clinical Data from the CARLYSLE Trial in Patients with Severe Refractory Systemic Lupus Erythematosus at the American Society of Hematology (ASH) Annual Meeting 2025 Data show deep, durable responses in the 50 million cell dose level cohort; initial data suggest substantial early improvement in three patients dosed with 100 million cellsAll patients show deep B-cell depletion after infusion, suggesting an immune resetNine patients were evaluable for safety, no ICANS or high-grade CRS were observed LONDON and GAITHERSBURG, Md., Dec. 08, 2025 (GLOBE NE...

 PRESS RELEASE

Autolus Therapeutics Presents Initial Clinical Data in Pediatric r/r B...

Autolus Therapeutics Presents Initial Clinical Data in Pediatric r/r B-ALL Patients and Other Oncology Data at the American Society of Hematology (ASH) Annual Meeting 2025 Obe-cel demonstrates high remission rates in pediatric patients with high-risk r/r B-ALL with overall response rate (ORR) of 95.5%; low rates of high-grade cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) observed, consistent with obe-cel’s adult safety profile FELIX study data analyses highlight product cell phenotype and level of CAR T persistence at three months as pote...

Guy Sips ... (+3)
  • Guy Sips
  • Jacob Mekhael
  • Wim Lewi
 PRESS RELEASE

Autolus Therapeutics Appoints Ryan Richardson to Board of Directors

Autolus Therapeutics Appoints Ryan Richardson to Board of Directors LONDON and GAITHERSBURG, Md., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announced the appointment of Ryan Richardson to the Company’s Board of Directors. Mr. Richardson brings more than 20 years of strategy and corporate development experience and in the healthcare and investment banking industries to Autolus’ Board. “Autolus has entered a new pha...

Jacob Mekhael
  • Jacob Mekhael

Autolus NICE recommends Aucatzyl for r/r adult B-ALL in England and Wa...

Autolus announced that the National Institute for Health and Care Excellence (NICE) has published draft guidance recommending Aucatzyl (obe-cel, CD19 CAR-T) for use in the National Health Service (NHS) in England and Wales as a treatment option for adult patients (=26 years) with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (r/r B-ALL). Aucatzyl will be available through routine commissioning by the NHS, and Autolus intends to launch the product in England and Wales immi...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch